Rare cancer hope: immune drug shows promise in phase 2 trial
NCT ID NCT02721732
First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 1 time
Summary
This study tested a drug called pembrolizumab in 157 people with rare cancers that had spread or couldn't be removed. The drug works by helping the body's immune system attack the cancer. The main goal was to see how many patients were alive and their cancer hadn't grown after 27 weeks of treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT SOLID NEOPLASM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a protein calm the immune System's overreaction to cancer treatment?
- Can a tracer that hunts unstable iron light up hidden tumors?
- New drug combo aims to shrink Hard-to-Treat pancreatic and ovarian tumors
- Engineered immune cells take aim at Hard-to-Treat cancers
- Immunotherapy drug keytruda takes on mysterious cancers of unknown origin
- Vaccine trains immune system to hunt down cancer cells